April 2019

  • Next act in genomics: the consumer orders

    April 2019—For years, laboratories have chafed against testing being, literally and figuratively, an out-of-sight, out-of-mind transaction. Now a new, highly visible era in genetics may be pushing testing the other way, into the hands of consumers who value entertainment as well as medical information. Anyone who wants to write a book about this shift has a ready-made title: From Basement to Big Top. It’s not that clinical testing is becoming an actual circus. But ever since the first consumer genetic tests entered the market in 2007—in a nonphysician-ordered, SNP array technology way—labs, physicians, and regulatory agencies have had plenty to juggle.

    Read More »
  • Microscopy’s dangers: From wear and tear to disabling injury

    April 2019—When pathologist Sandra Ewaskow, MD, was asked at a recent medical conference what topic she would choose if she were to write a book in her field, she thought of her own experience with musculoskeletal pain and of her mother, who had recently been hospitalized for occupational therapy after a hip fracture.

  • Study gauges impact of genotyping on gonorrhea treatment

    April 2019—Genotypic testing for ciprofloxacin susceptibility in Neisseria gonorrhoeae has been proved to be effective in guiding physician treatment in a single-center study at UCLA Health.

  • Too few technologists: labs take inventive steps

    April 2019—The tight supply of technologists to fill open positions is pushing laboratories to be creative in finding answers. Memorial Sloan Kettering Cancer Center and TriCore Reference Laboratories found their answers by looking not just outward but also—and largely—inward.

Image Credits: lorem ipsum, Procust, Month issue, etc..

IN EVERY ISSUE

  • Put It on the Board

    Shield launches test 
for antibiotic susceptibility 
in N. gonorrhoeae
    April 2019—Shield Diagnostics launched Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae. “Rapid molecular testing for ciprofloxacin resistance allows for smarter medicine,” Jeffrey D. Klausner, MD, MPH, a professor of infectious disease medicine at the University of California, Los Angeles, said in a Shield statement. “Right now we’re treating gonorrhea with a sledgehammer; we’re treating everything with the same exact regimen. And it’s not a surprise that the organism will become resistant to what we’re currently using.” Ciprofloxacin can be used to treat 80 percent of infections and is 99.8 percent effective when susceptibility has been determined. Because it is administered as a single oral dose, rather than the current injectable treatment, clinicians can prescribe antibiotics for the patient to give to their partners. “Shield has launched Target-NG to help clinicians adopt a precision medicine approach to gonorrhea treatment,” said Nidhi Gupta, PhD, lead scientist on the project.

    Read More »
  • Selected Pathology Abstracts
    Clinical pathology: Trauma resuscitation considerations: gender as a biological variable. Read more.
    Anatomic pathology: Frequent GNAQ and GNA14 mutations in hepatic small vessel neoplasm. Read more.
    Molecular pathology: Variants in NUDT15: association with thiopurine–induced myelosuppression. Read more.

  • Q&A column

    Q. Can you describe the contemporary significance and use of osmolality testing in the clinical laboratory? Read answer.
    Q. Is it necessary to include a comment on the patient report indicating that a test result was obtained after dilution? Read answer.

  • Newsbytes

    April 2019—The R&B classic “Time Is on My Side” may be an anthem for rejected lovers, but a new virtual reality teaching tool that allows students to “visit” the pathology lab without leaving the classroom may soon have NYU medical students humming the song’s refrain.

  • Click to view these CAP TODAY departments:
    President’s Desk
    Marketplace

Image Credits: lorem ipsum, Procust, Month issue, etc..

CAP TODAY Recommends

  • Roche Tissue Diagnostics art exhibit: “Uncommon Beauty”

    “Uncommon Beauty: Pathology and Other Microscopic Wonders and Realities in Nature,” the current exhibit at Roche Tissue Diagnostics’ Ventana Gallery, showcases a collaboration between pathologist Marilyn Bui, MD, PhD, senior member of pathology and president of the medical staff, Moffitt Cancer Center, and her patient artist Raymond Paul, both from Tampa, Fla. When Paul was diagnosed with sarcoma in 2011, he expressed a desire to see truly what his disease looked like. Dr. Bui invited him to view his tumor through a double-headed microscope and provided him with digital images that would become his inspiration for a series of large-scale abstract paintings.

    Read More »
  • Cancer Biomarkers Conference IV

    The Cancer Biomarkers Conference series provides real-world practical updates for general community pathologists, molecular pathologists, oncologists, and related specialties and professions. The conference features lectures and panel discussions on specific biomarker testing in solid and hematologic malignancies for tyrosine kinase inhibitors and immune therapies, liquid biopsy, next-generation sequencing, preanalytic management, billing, regulations, and malpractice for everyday practice and includes the needs and expectations of the oncologist.

  • Luminex offers white paper on preventing CDI

    A white paper titled “Can Global Testing for C. difficile Carriers Help to Prevent Healthcare-associated CDI?” from Luminex discusses the results of two recent studies that show that performing C. difficile testing only in patients with clinically significant diarrhea may be missing an opportunity to prevent CDI transmission from asymptomatic carriers. Download the white paper.

Image Credits: lorem ipsum, Procust, Month issue, etc..

Cytopathology

  • Cytopathology in focus: How can a lab ensure individual competence?

    January 2019—It is happening again: CAP members and cytotechnologists are asking about regulatory requirements for re-integrating into cytopathology after a period of practice latency. That is good news because it indicates that they are interested in practicing at a time when the cytopathology community can use skilled professionals. The past decade has seen a shrinking volume of Pap tests and a concomitant decline in the number of practicing cytologists, which has created new job opportunities for those with cytopathology skills.

    Read More »
  • Cytopathology in focus: Serous fluid cytology and the international system

    January 2019—Just when you thought you were done implementing a new terminology for cytology, another one pops up. Is it possible there are sites that have not yet been standardized? Unbelievably, the most common nongynecologic cytology specimen, body fluids, remains a Wild West for terminology.

  • Cytopathology in focus: Three special reports capture a field in transition

    January 2019—In the September/October 2018 issue of the Journal of the American Society of Cytopathology are three special reports from the American Society of Cytopathology/American Society for Clinical Pathology workgroup on current practices and future perspectives for the field of cytotechnology.

Image Credits: lorem ipsum, Procust, Month issue, etc..

MARKETPLACE

  • Luminex acquires MilliporeSigma’s flow cytometry portfolio

    April 2019—Luminex has completed its acquisition of MilliporeSigma’s flow cytometry portfolio for $75 million. The flow cytometry portfolio includes the Amnis family of imaging flow cytometry products for cell-based analysis and the Guava portfolio of microcapillary flow cytometry systems. “The Amnis and Guava products complement our wide range of existing flow-based offerings, further differentiating our portfolio and ensuring we are well positioned to support customers today and into the future,” Homi Shamir, president and CEO of Luminex, said in a press release. “With this acquisition, we now have expanded our installed base to include more than 5,000 flow cytometry systems worldwide, adding to our impressive footprint and creating the potential for additional meaningful growth.” The buyout is expected to contribute $40–$50 million in revenue to Luminex this year.

    Read More »
  • Bio-Rad quality control for urinalysis testing

    April 2019—Bio-Rad Laboratories announced the launch of Quantify Advance Control, an independent quality control used to monitor the precision of laboratory urinalysis test procedures. The control contains human urine solution and offers 31 days of open vial stability for all analytes, including ketones, at room temperature.

  • FDA approves Herceptin for subcutaneous use

    April 2019—The Food and Drug Administration approved trastuzumab and hyaluronidase-oysk (Herceptin Hylecta, Genentech) for subcutaneous injection for the treatment of certain people with HER2-positive early breast cancer in combination with chemotherapy and HER2-positive metastatic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease.

Image Credits: lorem ipsum, Procust, Month issue, etc..

X